RVVC
Conditions
Interventions
Sponsors
The Fifth Affiliated Hospital of Southern Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1 RVVC group (1) Those who meet the above-mentioned diagnostic criteria and are classified into spleen deficiency and dampness syndrome or damp-heat syndrome. (2) Female, aged 20-45, married or having sex, with regular and normal menstrual cycles. (3) At least 2 or more symptoms or signs of VVC, 4 or more episodes of VVC in the past year. (4) No antibiotics and probiotics were used in the two weeks before selection. (5) Those who voluntarily participate and sign the informed consent. 2 VVC group (1) Those who meet the above-mentioned diagnostic criteria and are classified into spleen deficiency and dampness syndrome or damp-heat syndrome. (2) Female, aged 20-45, married or having sex, with regular and normal menstrual cycles. (3) Examination of vaginal secretions: positive for Candida, at least 2 or more symptoms or signs of VVC, no history of VVC attacks in the past year. (4) No antibiotics and probiotics were used in the two weeks before selection. (5) Those who voluntarily participate and sign the informed consent. 3 Normal control group (1) Female, aged 20-45, married or having sex, with regular and normal menstrual cycles. (2) Select healthy non-pregnant women. (3) Examination of vaginal discharge: negative. (4) No antibiotics and probiotics were used in the two weeks before selection. (5) Those who voluntarily participate and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Women during pregnancy and lactation; 2. Patients suffering from diabetes and oral contraceptives; 3. Patients with severe disease of the heart, liver, kidney and other major organs, hematopoietic diseases, and tumors who cannot guarantee the smooth progress of this study; 4. Those who are unable to cooperate, such as those who have a history of neurological and mental illness or are unwilling to cooperate; 5. Those who have received systemic antifungal treatment within 3 months or have received topical antifungal treatment within 1 month; 6. Those who have immunological diseases or are taking immunosuppressants or regulators, or those who have been vaccinated one year before joining the group; 7. Mixed vaginal infection: such as mixed trichomoniasis, bacterial vaginitis, mycoplasma, chlamydia infection; 8. Subjects who are participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vaginal microecology; | — |
Countries
China
Contacts
Public ContactRuan Lijun
The Fifth Affiliated Hospital of Southern Medical University
Outcome results
None listed